Dare Bioscience, Inc. revenue
Dare Bioscience, Inc.'s revenue was $1.0m in fiscal 2025, up 10429.4% on the year before. Since fiscal 2012 ($625,000) it has grown at a compound 6.4% a year. Over the last twelve months it was $1.4m.
Revenue history
| Fiscal year | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2016Dec 2016 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1 | 0 | 0 | 1 | 0 | 10 | 3 | 0 | 1 | 1 |
| Growth on the year before | — | −99.0% | +>999% | +857.5% | −100.0% | — | −71.9% | −99.7% | +>999% | — |
| Gross profit | — | — | — | — | — | — | — | 0 | 1 | — |
| Gross margin | — | — | — | — | — | — | — | 100.0% | 71.3% | — |
Where the revenue comes from
| Line of business | Revenue | YoY |
|---|---|---|
| License and Collaboration Revenues | $12M | — |
| Licenses | $1M | ▲ 10429.4% |
These categories overlap or exclude eliminations, so shares aren't shown.
From Dare Bioscience, Inc.'s 10-K filed March 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Dare Bioscience, Inc. | $1.4m | 4366.5% | — |
| Cartesian Therapeutics, Inc. | $1.5m | 44.0% | -68.8% |
| Absci Corp | $1.6m | -62.3% | -43.3% |
| Longeveron Inc. | $1.2m | -42.7% | 10.4% |
| Ovid Therapeutics Inc. | $1.6m | -76.2% | 99.8% |
| Shattuck Labs, Inc. | $1.0m | -66.6% | 5.2% |
Compare with peers
- Cartesian Therapeutics, Inc. revenue
- Absci Corp revenue
- Longeveron Inc. revenue
- Ovid Therapeutics Inc. revenue
- Shattuck Labs, Inc. revenue
Head to head: DARE vs RNACABSI vs DAREDARE vs LGVNDARE vs OVID
More: Biotechnology stocks compared, Health Care sector, rankings of US companies